Insights on Molecular Heterogeneity in Endometriosis Treatment – HER Heard
HER Heard shared a post by Femtech Insider on LinkedIn:
“Important breakthrough in our understanding of Endometriosis: ‘Endometriosis is currently classified based on symptoms and anatomical or surgical features, but these approaches don’t capture the biological programs active inside the tissue. Our work shows that what looks like unpredictable variability between patients actually reflects recurring cellular states that shape how the disease behaves and responds to treatment. This creates an opportunity to move toward more biologically informed patient stratification in research and clinical trials.'”
Quoting Femtech Insider’s post, adding:
“France-based biotech endogene.bio has published research suggesting that endometriosis is molecularly heterogeneous across patients, lesion sites, and cell types – a finding that could help explain why patients often experience different outcomes with the same therapy.
The preprint, titled ‘Beyond one-size-fits-all: single-cell transcriptomic signatures predict drug efficacy and reveal responder subgroups in endometriosis,’ combines single-cell RNA sequencing with a computational drug-response framework to identify distinct cellular response patterns that may predict which therapies are most likely to work for specific patient groups.
‘Endometriosis is currently classified based on symptoms and anatomical or surgical features, but these approaches don’t capture the biological programs active inside the tissue. Our work shows that what looks like unpredictable variability between patients actually reflects recurring cellular states that shape how the disease behaves and responds to treatment. This creates an opportunity to move toward more biologically informed patient stratification in research and clinical trials.’ Cristina Fernández Molina, Co-founder and Head of Science at endogene.bio
Full story.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Mar 3, 2026, 00:23Final Call for Review of Updated ESHRE IVF Laboratory Recommendations – ESHRE
-
Mar 3, 2026, 00:15Abstract Submissions Are Now Open for ASM 2026! – BSGI
-
Mar 2, 2026, 14:06Ever Wondered How Ovulation Works? Let’s Break It Down! – Fertility Plus
-
Mar 2, 2026, 13:48Join RBMO Webinar on Global Declining Fertility Rates – RBMO
-
Mar 2, 2026, 13:39Governance of Polygenic Embryo Screening – Fertility and Sterility
-
Mar 2, 2026, 13:26AJOG MFM February 2026 Podcast Episode Is Out!
-
Mar 2, 2026, 13:21Yousef Zakharia Leads Clinical Research Aimed at Genitourinary Cancers – Mayo Clinic
-
Mar 1, 2026, 16:41Exploring Frozen and Fresh Embryo Transfer Risks – Fertility and Sterility
-
Mar 1, 2026, 16:40Foraviset Welcomes Prof. Tasuku Harada to Advisory Board – Foraviset
